Abstracts

TDF and Efavirenz but Not InSTI or TAF Use Are Associated With Weight Gain During cART

Background: Combination antiretroviral therapy (cART) containing integrase strand transfer inhibitors (INSTIs) and/or tenofovir alafenamide (TAF) has been associated with greater weight gain (WG) than cART without these drugs. Yet few studies have adjusted for multiple individual antiretrovirals (ARV) and for both anchor and backbone ARV component. Methods: We studied WG in cART-naïve patients by analyzing…

Switching to Integrase Strand Transfer Inhibitors and the Risk of Diabetes in Persons With HIV

Background: Integrase strand transfer inhibitors (INSTIs) are commonly used antiretroviral therapy (ART) among people with HIV (PWH). INSTI use is associated with weight gain, hyperglycemia, and diabetes among ART-naïve PWH. We estimated the risk of incident diabetes associated with switching from a non-nucleoside reverse-transcriptase inhibitor (NNRTI) or protease inhibitor (PI) to an INSTI. Methods: We…

Dolutegravir Targets the Hypothalamus to Suppress Energy Expenditure via Estrogen Receptor

Background: Antiretroviral therapy (ART) containing integrase strand transfer inhibitors (INSTI) has been associated with weight gain in both ART-initiation and switch studies, especially in women, but the underlying mechanisms are unclear. Estrogen promotes energy expenditure via suppressing AMP-dependent kinase (AMPK) in the hypothalamus and yet very few studies are available examining the central effects of…

Subcutaneous Adipose Tissue Myofibroblasts Are Associated With the Lipidome

Background: Dyslipidemia is common in persons with HIV (PWH) and mechanistically linked to the development of metabolic disease. Higher plasma triacylglycerides (TG) are associated with the diabetes, while an inverse relationship is observed for sphingomyelin (SM) and phosphatidylcholine (PC) species. Adipose tissue has a critical role in regulating lipid homeostasis, but how adipose tissue cellular…

Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy

Background: Lipohypertrophy (central adipose tissue (AT) accumulation) is a common and significant problem in people with HIV (PWH). We previously demonstrated that semaglutide, a glucagon-like peptide-1 receptor agonist, significantly decreased central AT in PWH with lipohypertrophy, primarily driven by reductions in visceral AT. Here, we assessed the effects of semaglutide on inflammation and immune activation…

Hypertension Treatment Gap Among People With/Without HIV in Kenya, Nigeria, Tanzania, and Uganda

Background: Mortality associated with hypertension (HTN) in sub-Saharan Africa is among the highest globally and unlike other regions, little progress has been made in diagnosis, treatment, and control. HIV care programs have typically focused on providing HIV-related care, but as life expectancies of people with HIV (PWH) are extending, addressing noncommunicable diseases and risk factors…

No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for HIV PrEP in HPTN 083

Background: Results from some trials of HIV treatment suggest an excess risk of hypertension (HTN) associated with integrase strand transfer inhibitors (INSTIs), independent of changes in weight or BMI. HPTN 083, in HIV-negative MSM and transgender women, compared injectable cabotegravir (CAB) to daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV PrEP. We performed a post-hoc…